Putative Transport Mechanism and Intracellular Fate of Trans-1-Amino-3-18F-Fluorocyclobutanecarboxylic Acid in Human Prostate Cancer

Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti–18F-FACBC) is an amino acid PET tracer that has shown promise for visualizing prostate cancer. Therefore, we aimed to clarify the anti–18F-FACBC transport mechanism in prostate cancer cells. We also studied the fate of anti–18F-FACBC after it is transported into cells. Methods: For convenience, because of their longer half-lives, 14C compounds were used instead of 18F-labeled tracers. Trans-1-amino-3-fluoro-1-14C-cyclobutanecarboxylic acid (14C-FACBC) uptake was examined in human prostate cancer DU145 cells with the following substrates of amino acid transporters: α-(methylamino) isobutyric acid (a system A–specific substrate) and 2-amino-2-norbornanecarboxylic acid (a system L–specific substrate). The messenger RNA expression of amino acid transporters in human prostate cancer specimens was analyzed by complementary DNA microarray and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Gene expression in DU145 cells was analyzed by qRT-PCR. We also examined the knockdown effect of the amino acid transporters system ASC transporter 2 (ASCT2) and sodium-coupled neutral amino acid transporter 2 (SNAT2) on 14C-FACBC uptake. In addition, the possibility of 14C-FACBC incorporation into proteins was examined. Results: 14C-FACBC uptake by DU145 cells was markedly decreased to approximately 20% in the absence of Na+, compared with that in its presence, indicating that Na+-dependent transporters are mainly responsible for the uptake of this tracer. Moreover, 2-amino-2-norbornanecarboxylic acid inhibited the transport of 14C-FACBC to the basal level in Na+-free buffer. In contrast, α-(methylamino) isobutyric acid did not inhibit 14C-FACBC accumulation in DU145 cells. Human prostate tumor specimens and DU145 cells had similar messenger RNA expression patterns of amino acid transporter genes. Although SNAT2 and ASCT2 are 2 major amino acid transporters expressed in prostate tumor tissues and DU145 cells, ASCT2 knockdown using small interfering RNA was more effective in lowering 14C-FACBC transport than SNAT2. Almost all intracellular 14C-FACBC was recovered from the nonprotein fraction. Conclusion: ASCT2, which is a Na+-dependent amino acid transporter, and to a lesser extent Na+-independent transporters play a role in the uptake of 14C-FACBC by DU145 cells. Among the Na+-independent transporters, system L transporters are also involved in the transport of 14C-FACBC. Moreover, 14C-FACBC is not incorporated into proteins in cells. These findings suggest a possible mechanism of anti–18F-FACBC PET for prostate cancer.

[1]  Syuichi Nakajima,et al.  Uptake of 3-[125I]iodo-alpha-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs. , 2010, Nuclear medicine and biology.

[2]  Syuichi Nakajima,et al.  Stimulation of 125I-3-iodo-alpha-methyl-L-tyrosine uptake in Chinese hamster ovary (CHO-K1) cells by tyrosine esters. , 2010, Nuclear medicine and biology.

[3]  J. Votaw,et al.  Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma , 2009, Molecular Imaging and Biology.

[4]  E. Malveaux,et al.  Stereoselective synthesis and biological evaluation of syn-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent. , 2009, Bioorganic & medicinal chemistry.

[5]  T. Matsuda,et al.  Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. , 2008, Japanese journal of clinical oncology.

[6]  C. Grewer,et al.  Highly Conserved Asparagine 82 Controls the Interaction of Na+ with the Sodium-coupled Neutral Amino Acid Transporter SNAT2* , 2008, Journal of Biological Chemistry.

[7]  B. Fuchs,et al.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? , 2005, Seminars in cancer biology.

[8]  Heiko Schöder,et al.  Positron emission tomography for prostate, bladder, and renal cancer. , 2004, Seminars in nuclear medicine.

[9]  S. Bröer,et al.  Molecular Cloning of Mouse Amino Acid Transport System B0, a Neutral Amino Acid Transporter Related to Hartnup Disorder* , 2004, Journal of Biological Chemistry.

[10]  B. Mackenzie,et al.  Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family , 2004, Pflügers Archiv.

[11]  D. Witte,et al.  Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. , 2002, Anticancer research.

[12]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  V. Ganapathy,et al.  Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. , 2000, Biochimica et biophysica acta.

[14]  S. Mager,et al.  Cloning and Functional Expression of a Human Na+and Cl−-dependent Neutral and Cationic Amino Acid Transporter B0+ * , 1999, The Journal of Biological Chemistry.

[15]  J. Votaw,et al.  Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Palacín,et al.  Molecular biology of mammalian plasma membrane amino acid transporters. , 1998, Physiological reviews.

[17]  J. Thie,et al.  Positron Emission Tomography (PET) with 1-Aminocyclobutane-1-[(11)C]carboxylic Acid (1-[(11)C]-ACBC) for Detecting Recurrent Brain Tumors. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[18]  Y. Kanai,et al.  Cloning and Functional Characterization of a System ASC-like Na+-dependent Neutral Amino Acid Transporter* , 1996, The Journal of Biological Chemistry.

[19]  J. S. Laughlin,et al.  Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in patients with malignant melanoma. , 1991, American journal of physiologic imaging.

[20]  M. Saier,et al.  Neutral amino acid transport systems in animal cells: Potential targets of oncogene action and regulators of cellular growth , 1988, The Journal of Membrane Biology.

[21]  G. Antoni,et al.  Synthesis of L- and D-[methyl-11C]methionine. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  J. Anon,et al.  Effect of structure on tumor specificity of alicyclic alpha-amino acids. , 1978, Cancer research.

[23]  R. Laferte,et al.  Biochemical studies of an unnatural and antitumor amino acid: 1-aminocyclopentanecarboxylic acid. II. Effects on cellular respiration and amino acid metabolism. , 1962, Canadian journal of biochemistry and physiology.

[24]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[25]  S. Bröer Amino acid transport across mammalian intestinal and renal epithelia. , 2008, Physiological reviews.

[26]  F DuBois Bowman,et al.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  J. Votaw,et al.  A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  T. Matsuda,et al.  Comparison of time trends in prostate cancer incidence (1973 1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. , 2007, Japanese journal of clinical oncology.

[29]  A. Bröer,et al.  The orphan transporter v7-3 (slc6a15) is a Na+-dependent neutral amino acid transporter (B0AT2). , 2006, The Biochemical journal.

[30]  Mithat Gonen,et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.